<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Patients with severe <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> are thought to be ineligible for cord blood stem cell transplantation (CBT) because the conventional 5-6 day-conditioning regimens potentially makes them susceptible to fatal <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> by the time neutrophil engraftment occurs </plain></SENT>
<SENT sid="1" pm="."><plain>Two patients were treated with minimum conditioning regimens consisting of 30 mg/m(2) fludarabin (Flu) and 2 g/m(2) <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> (CY) on day-1 and total body irradiation (TBI) of 2 or 4 Gy on day -1 or 0 followed by single unit CBT </plain></SENT>
<SENT sid="2" pm="."><plain>The reasons for adopting such weak regimen were febrile <z:hpo ids='HP_0001875'>neutropenia</z:hpo> due to the rejection of the first cord blood (CB) graft given to a patient with follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> resistant to chemotherapy and <z:e sem="disease" ids="C0004031" disease_type="Disease or Syndrome" abbrv="">pulmonary aspergillosis</z:e> in another patient with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> who relapsed after CBT </plain></SENT>
<SENT sid="3" pm="."><plain>The <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patient received 40 mg/m(2) of melphalan on day-2 to reduce the <z:hpo ids='HP_0001909'>leukemia</z:hpo> burden </plain></SENT>
<SENT sid="4" pm="."><plain>Both patients achieved 100% donor chimerism by day 19 and day 20 after CBT without an apparent exacerbation of the <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> and remained in remission at 23 and 18 months after the CBT </plain></SENT>
<SENT sid="5" pm="."><plain>These findings suggest that the 1-2 day regimens excluding antihuman thymocyte globulin may be sufficiently potent to ensure engraftment of CB in immunocompromised patients and safely administered even when patients are complicated by active <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> </plain></SENT>
</text></document>